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Aims There are limited and contradictory data on the effects of CRT with implantable cardioverter defibrillator (CRT-D)
on mortality as compared with CRT with pacemaker (CRT-P).
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Methods
and results
We evaluated the long-term outcome of patients implanted with a CRT-D or CRT-P device in our high-volume
single-centre experience. Data on all-cause mortality were derived from clinic visits and the Hungarian National
Healthcare Fund Death Registry. Kaplan–Meier survival analyses and multivariate Cox regression models were used
to evaluate all-cause mortality in patients with CRT-D vs. CRT-P, stratified by the aetiology of cardiomyopathy. From
2000 to 2011, 1122 CRT devices, 693 CRT-P (LVEF 28.2± 7.4%) and 429 CRT-D (LVEF 27.6± 6.4%), were implanted
at our centre. During the median follow-up of 28 months, 379 patients died from any cause, 250 patients (36%)
with an implanted CRT-P and 129 patients (30%) with an implanted CRT-D. There was no evidence of mortality
benefit in patients implanted with a CRT-D compared with a CRT-P in the total cohort [hazard ratio (HR) 0.98, 95%
confidence interval (CI) 0.73–1.32, P= 0.884]. In patients with ischaemic cardiomyopathy, CRT-D treatment was
associated with a significant 30% risk reduction in all-cause mortality compared with an implanted CRT-P (HR 0.70,
95% CI 0.51–0.97, P= 0.03). In non-ischaemic patients, there was no mortality benefit of CRT-D over CRT-P (HR
0.98, 95% CI 0.73–1.32, P= 0.894, interaction P-value= 0.15).
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Conclusions In heart failure patients with ischaemic cardiomyopathy, CRT-D was associated with a mortality benefit compared
with CRT-P, but no benefit of CRT-D over CRT-P in mortality was observed in non-ischaemic cardiomyopathy.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Cardiac resynchronization therapy with or without a defibrillator
(CRT-D vs. CRT-P) has been shown to reduce morbidity and mor-
tality in selected patients with heart failure and severely reduced LV
function, as demonstrated in several randomized clinical trials.1–4
However, the decision of whether to implant a CRT-D or a
CRT-P device has long been a controversial issue. There have
been no randomized trials adequately powered that were directly
comparing clinical outcome between patients implanted with a
CRT-D vs. a CRT-P.
The Comparison of Medical Therapy, Pacing, and Defibrillation in
Heart Failure (COMPANION) trial investigated CRT-D implanta-
tion vs. optimal medical therapy and CRT-P implantation vs. optimal
medical therapy alone, but the trial did not evaluate the efficacy
of CRT-D over CRT-P and it was not designed to answer this
question.4 Several meta-analyses comparing the efficacy of CRT-D
over CRT-P in patients with a primary indication for an implantable
cardioverter defibrillator (ICD) have failed to show an incremental
benefit of adding the defibrillator option to CRT.5–7 In addition,
CRT-D devices have a higher cost and a lower cost–benefit ratio,8
and the complexity of the defibrillator leads in CRT-D systems may
result in a higher risk of lead-related complications.8
Currently there is no consensus regarding the optimal patient
selection for CRT-P therapy alone. Due to financial constraints,
in many emerging countries physicians implant CRT-P devices in
as many as 50% of their patients who would otherwise qualify
for implantation of a CRT-D device by contemporary guidelines.9
Analyses identifying patient subgroups who might benefit from the
implantation of a CRT-P alone are lacking and warranted.
In this high-volume single-centre CRT registry, we aimed to
evaluate the effects of CRT-D vs. CRT-P on all-cause mortality in
the total patient cohort and stratified by ischaemic aetiology of
cardiomyopathy, as a pre-specified analysis. We hypothesized that
CRT-D is associated with more pronounced mortality benefit in
patients with an ischaemic aetiology of cardiomyopathy compared
with CRT-P due to the reduction in sudden cardiac death (SCD).
Methods
Patient population
Between June 2000 and April 2011, a total of 1122 consecutive patients
underwent CRT device implantation at the Semmelweis University
Heart and Vascular Center, Budapest, Hungary. Patients undergoing
CRT implantation had NYHA class II, III, or IV heart failure symptoms,
QRS ≥120ms, LVEF ≤35%, and they were on optimal medical therapy
including beta-blocker, ACE inhibitor, or ARB therapy, diuretics, and an
aldosterone antagonist, unless contraindicated or not tolerated by the
patient.10,11 Medical therapy was optimized in all patients according to
current guidelines.12 All patients provided written informed consent
before the procedure.
Pre-implant assessment
Baseline clinical characteristics were recorded prior to CRT implan-
tation. Clinical evaluation included NYHA functional class and quality ..
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.. of life assessment, the latter using EuroQol (EQ-5D) quality of
life questionnaires.13 Two-dimensional transthoracic echocardiography
was performed before CRT implantation and during follow-up using
commercially available systems (Toshiba Aplio, Toshiba Medical Systems
Co., Ltd, Tokyo, Japan; and Philips iE33, Andover, MA, USA). Patients
had echocardiographic evaluation in the left lateral decubitus position
under resting conditions. LV end-diastolic and end-systolic diameters
(LVEDD and LVESD) were measured according to standard methods.14
LVEF was calculated from the apical four-chamber view images, using
the Simpson disk method. Measurements were performed by the
physician acquiring the echo images. Additionally, diagnostic coronary
angiography and coronary artery revascularization was performed in
all of our patients to exclude the need for coronary revascularization
and to define the aetiology of cardiomyopathy.
Device implantation
Implantation of a CRT-D vs. a CRT-P device was left to the physician’s
discretion. Implantation of CRT devices was performed using the
transvenous, epicardial, or transseptal approach. In patients in sinus
rhythm or those with paroxysmal AF, a right atrial lead and a right ven-
tricular lead were implanted, while patients in permanent AF received
only right and left ventricular leads. During the implantation procedure,
after cannulating the coronary sinus, a balloon catheter was used to
perform coronary sinus venography in order to identify target veins for
the LV lead. LV lead implant into the lateral or postero-lateral branch
was preferred. The right ventricular lead was preferably implanted
in the right septal position. LV pacing, sensing, and impedance values
were measured. Phrenic nerve stimulation of the LV lead was tested
in a supine position with 10 V at 2ms pacing in the left ventricle.
In patients with intraoperative LV lead dislodgement or phrenic
nerve stimulation, repositioning and stabilization of the LV lead with
a coronary stent implantation was performed using the technique
developed at our centre, as previously reported.15
Commercially available LV leads and CRT devices were used. If the
patient received a CRT-D device, defibrillation threshold testing was
performed at implantation in order to achieve a safety margin of at
least 10 J.
Post-implant assessment
All patients were scheduled for an outpatient visit 1month after device
implantation and every 6 months thereafter. Clinical status assessment
and device follow-up were performed at each follow-up visit and at any
meaningful clinical event.
Study endpoints
The primary endpoint of the present analysis was all-cause mortality.
The secondary endpoint was improvement in LVEEF as assessed by
echocardiography at the last available follow-up, compared with the
baseline LVEF. Data on mortality were collected from medical records
and using the Hungarian National Health Fund Death Registry.
Statistical analysis
Continuous variables are expressed as the mean± SD. Categorical
data are summarized as frequencies and percentages. Baseline clinical
characteristics were compared between the subgroups, stratified by
CRT-D or CRT-P implant using non-parametric Wilcoxon test for
continuous variables and the 𝜒2 test for dichotomous variables.
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Improvement in LVEF after device implantation, stratified by aetiol-
ogy of cardiomyopathy, was compared using non-parametric Wilcoxon
test, as appropriate.
The cumulative probability of survival was determined according to
the Kaplan–Meier method in CRT-D and CRT-P patients, with com-
parisons of cumulative event rates by the log-rank test, and in the sub-
groups of patients with ischaemic and non-ischaemic cardiomyopathy.
Multivariate Cox proportional hazards regression analysis was used
to evaluate the effect of implanted CRT-D or CRT-P device on the
risk of mortality after adjustment for relevant clinical covariates that
were found to be imbalanced at baseline. Interaction P-values between
ischaemic and non-ischaemic patients were computed and reported
to evaluate the effect of CRT-D vs. CRT-P on mortality in these
subgroups.
Adjusted hazards ratios (HRs) with their 95% confidence intervals
(CIs) are reported. A P-value <0.05 was considered statistically signif-
icant. Analyses were carried out with SAS software (version 9.3, SAS
institute, Cary, NC, USA).
Results
Baseline clinical characteristics
Baseline clinical characteristics of patients who underwent CRT-D
vs. CRT-P implantation are listed in Table 1. During the 10-year
time period, 693 CRT-P (62%) and 429 CRT-D (38%) devices
were implanted. Mean patient age was 65±11 years and 262 (23%)
of them were women. We found a lower proportion of CRT-D
implantation vs. CRT-P in the early years (Supplementary material
online, Figure S1).
Patients with an implanted CRT-P were significantly older, were
more often females, and were less likely to have ischaemic car-
diomyopathy as compared with CRT-D patients. Accordingly, prior
myocardial infarction (MI), prior PCI, and prior coronary artery
bypass graft (CABG) were less prevalent in CRT-P patients.
Patients with CRT-P more often had permanent AF and were more
likely to have wider QRS complexes when compared with CRT-D
patients (165.5± 27.8ms vs. 158.2± 27.1ms, P< 0.001).
Renal function at baseline was similar in both groups. CRT-D
patients were more often prescribed aldosterone antagonists and
amiodarone than those with an implanted CRT-P. Baseline echocar-
diographic parameters including LVEF, LVEDD, and LVESD were
similar at baseline.
Device implantation
The CRT implantation procedure was performed using either a
transvenous (n= 1094, 97.5%), an epicardial (n= 17, 1.5%), or a
transseptal (n=11, 1%) approach. LV leads were implanted in
the lateral or postero-lateral side branch of the coronary sinus
in 630 (91%) CRT-P patients and in 395 (91%) CRT-D patients,
and in the anterior position in 48 (7%) CRT-P patients and 21
(5%) CRT-D patients (P-value >0.05 for the difference). Epicardial
LV lead placement was performed in 10 CRT-P and 7 CRT-D
patients, and the transseptal approach was used in 5 CRT-P
and 6 CRT-D patients after an unsuccessful transvenous LV lead
implantation. ..
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Table 1 Baseline clinical characteristics of patients
who received cardiac resynchronization therapy with
implantable cardioverter defibrillator and cardiac
resynchronization therapy with pacemaker
Clinical parameters CRT-D
patients
(n= 429)
CRT-P
patients
(n= 693)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age at enrolment (years) 63.9±10.9 66.3±10.5*
Female 68 (16) 194 (29)*
Ischaemic aetiology 220 (51) 235 (34)*
Secondary prevention 242 (56) 70 (10)*
QRS (ms) 158.2± 27.1 165.5± 27.8*
Diabetes mellitus 134 (31) 241 (35)
Hypertension 277 (65) 427 (62)
Prior MI 230 (54) 227 (33)*
Prior PCI 124 (29) 132 (19)*
Prior CABG 88 (21) 66 (10)*
Paroxysmal atrial fibrillation 69 (16) 94 (14)
Permanent atrial fibrillation 96 (22) 192 (28)*
Creatinine (μmol/L) 114.2± 43.6 117.1± 53.3
Urea (mM/L) 9.8± 5.1 10.3± 6.4
Medications
Beta-blockers 376 (88) 582 (84)
ACE inhibitor/ARB 367 (86) 583 (84)
Diuretics 328 (77) 522 (75)
Aldosterone antagonist 259 (61) 368 (53)*
Amiodarone 180 (42) 139 (20)*
Echocardiography
LVEF, % 27.6± 6.4 28.2± 7.4
LVEDD, mm 65.5± 9.8 64.2± 9.8
LVESD, mm 55.0± 10.1 53.6±10.5
Values are given as a percentage of patients or mean± SD.
CABG, coronary artery bypass graft; CRT-D, cardiac resynchronization therapy
with implantable cardioverter defibrillator; CRT-P, cardiac resynchronization
therapy with pacemaker; LVEDV, left ventricular end-diastolic volume; LVESV, left
ventricular end-systolic volume; MI, myocardial infarction.
*P< 0.05 for comparison between CRT-P and CRT-D patients.
During the implantation, LV pacing threshold, sensing param-
eters, and LV impedance values were determined, and all pac-
ing outputs were programmed to achieve adequate pacing safety
margins. In patients with intraoperative LV lead dislodgement
or phrenic nerve stimulation, repositioning and stabilization of
the coronary sinus lead was performed using coronary stent
implantation.
Echocardiographic response and quality
of life during follow-up in patients
with cardiac resynchronization therapy
with an implantable cardioverter
defibrillator vs. with a pacemaker,
stratified by aetiology of cardiomyopathy
Implantation of either a CRT-D or a CRT-P device was associated
with significant, similar improvement in LVEF (CRT-D 6.33± 9.25%
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Echocardiographic response to cardiac resynchroniza-
tion therapy with implantable cardioverter defibrillator (CRT-D)
vs. cardiac resynchronization therapy with pacemaker (CRT-P),
stratified by ischaemic aetiology.
vs. CRT-P 6.85±10.3%; P= 0.49) (Figure 1). Improvement in LVEF
was similar in non-ischaemic patients with an implanted CRT-P or
a CRT-D and in ischaemic patients with an implanted CRT-P or
a CRT-D. However, non-ischaemic patients derived a significantly
greater improvement in LVEF as compared with ischaemic patients
(P< 0.001) (Figure 1).
Patients had similar improvement in quality of life with an
implanted CRT-D vs. CRT-P in the total patient cohort (CRT-D,
0.20± 0.29 vs. CRT-P, 0.24± 0.29, P= 0.21), in ischaemic car-
diomyopathy patients (CRT-D, 0.22± 0.29 vs. CRT-P, 0.25± 0.33,
P= 0.67), and in non-ischaemic cardiomyopathy patients (CRT-D.
0.17± 0.28 vs. CRT-P. 0.23± 0.31, p= 0.14).
The risk of all-cause mortality
by aetiology of cardiomyopathy
Patients with ischaemic cardiomyopathy had a significantly higher
risk of all-cause mortality than those with non-ischaemic car-
diomyopathy (Figure 2A), with a 5-year 52% cumulative proba-
bility of death in patients with ischaemic cardiomyopathy com-
pared with 40% cumulative probability of death in patients with
non-ischaemic cardiomyopathy (P= 0.003) that translated to an
overall 40% increase in the risk of death model (P= 0.002).
The effect of in patients with cardiac
resynchronization therapy with an
implantable cardioverter defibrillator vs.
with a pacemaker on all-cause mortality
During the median follow-up of 28 months (interquartile range of
12–47 months), 378 (34%) patients died of any cause, 129 patients
(30%) in the CRT-D arm and 249 patients (36%) in the CRT-P
arm. The 5-year cumulative survival was 56% in the total patient
population. ..
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Figure 2 Cumulative probability of all-cause mortality (A) in
ischaemic vs. non-ischaemic cardiomyopathy patients and (B) in
patients with cardiac resynchronization therapy with implantable
cardioverter defibrillator (CRT-D) vs. cardiac resynchronization
therapy with pacemaker CRT-P).
Kaplan–Meier survival analysis of the total cohort stratified
by the implanted device is shown in Figure 2B. There was no
significant difference in the cumulative probability of all-cause
mortality between patients implanted with a CRT-D vs. a CRT-P
device, with a 5-year 42% cumulative probability of death in those
with an implanted CRT-D and 45% in those with an implanted
CRT-P (P log-rank= 0.531).
Univariate Cox analysis showed no difference in all-cause mor-
tality between patients implanted with a CRT-D vs. CRT-P (HR
0.94, 95% CI 0.76–1.16, P= 0.540). Multivariate analysis after
adjustment for ischaemic aetiology of cardiomyopathy, age at device
implantation, and gender revealed consistent results. There was
no mortality difference among patients implanted with a CRT-D
or a CRT-P in the total patient cohort (CRT-D HR 0.98, 95% CI
0.73–1.32, P= 0.884) (Table 2).
The effect of in patients with cardiac
resynchronization therapy with an
implantable cardioverter defibrillator vs.
with a pacemaker on all-cause mortality
by ischaemic etiology of cardiomyopathy
In patients with ischaemic cardiomyopathy, CRT-D implantation
was associated with a significantly lower cumulative probability of
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 The risk of all cause-mortality in patients with cardiac resynchronization therapy with implantable
cardioverter defibrillator vs. cardiac resynchronization therapy with pacemaker in the total cohort and stratified by
the aetiology of cardiomyopathy
Parameter Events/no. of patients Hazard ratio 95% CI P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total patient cohort
Unadjusted CRT-D: CRT-P 378 events 0.94 0.76–1.16 0.540
Adjusted CRT-D: CRT-P 378 events 0.98 0.73–1.32 0.884
Ischaemic cardiomyopathy
Unadjusted CRT-D: CRT-P 162 events 0.70 0.51–0.97 0.031
Adjusted CRT-D: CRT-P 162 events 0.70 0.50–0.97 0.032
Non-ischaemic cardiomyopathy
Unadjusted CRT-D: CRT-P 216 events 1.03 0.77–1.39 0.839
Adjusted CRT-D: CRT-P 216 events 0.98 0.73–1.32 0.894
Models are adjusted for age, gender, ischaemic aetiology of cardiomyopathy (main model only), and ischaemic aetiology–age–gender interaction.
Interaction P-value between ischaemic and non-ischaemic cardiomyopathy, unadjusted P= 0.099, adjusted P= 0.153.
CI, confidence interval; CRT-D, cardiac resynchronization therapy with implantable cardioverter defibrillator; CRT-P, cardiac resynchronization therapy with pacemaker.
Figure 3 Cumulative probability of all-cause mortality in
patients with cardiac resynchronization therapy with implantable
cardioverter defibrillator (CRT-D) vs. cardiac resynchronization
therapy with pacemaker (CRT-P) (A) in ischaemic cardiomyopathy
and (B) in non-ischaemic cardiomyopathy patients.
all-cause mortality as compared with CRT-P (5-year probability of
47% vs. 56%, P= 0.025) (Figure 3A).
In the univariate model, there was a 30% risk reduction in
all-cause mortality in patients with ischaemic cardiomyopathy
implanted with a CRT-D device when compared with patients
implanted with a CRT-P (Table 3) (HR 0.70, 95% CI 0.51–0.97, .
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.. P= 0.031). After adjustment for age and gender, similarly, the risk
reduction in all-cause mortality was 30% with an implanted CRT-D
vs. CRT-P in ischaemic patients (HR 0.70, 95% CI 0.50–0.97,
P= 0.032) (Table 2).
However, there was no significant difference in the cumulative
probability of death from any cause in patients with non-ischaemic
cardiomyopathy and an implanted CRT-D compared with those
implanted with a CRT-P (Table 4) (P= 0.81) (Figure 3B). In patients
with non-ischaemic cardiomyopathy, implantation of a CRT-D did
not result in a beneficial reduction in mortality over what was
observed with implant of a CRT-P device [unadjusted and adjusted
HR 1.03 and 0.98, P= non-significant (NS) for both] (Table 2).
There was a borderline significant difference in mortality reduc-
tion with CRT-D in patients with ischaemic cardiomyopathy com-
pared with those with non-ischaemic cardiomyopathy (unadjusted
interaction P-value= 0.099, adjusted interaction P-value= 0.153),
suggestive of an incremental beneficial effect of CRT-D over CRT-P
in ischaemic patients, but not in patients with non-ischaemic car-
diomyopathy.
Discussion
We have shown in our 10-year high-volume, single-centre registry
data that CRT-D is associated with a significant mortality benefit
in patients with ischaemic cardiomyopathy above and beyond the
benefit attained with CRT alone without defibrillator therapy.
However, in patients with non-ischaemic cardiomyopathy, CRT-D
implantation was not associated with mortality benefit beyond
what was achieved with CRT-P alone in our registry. In the total
cohort of patients, the extent of CRT-induced improvements in
LVEF was similar in patients receiving either a CRT-D or CRT-P
device, although the subset of patients with non-ischaemic car-
diomyopathy had much greater improvements in cardiac function
with CRT.
Previous randomized multicentre clinical studies evaluated the
effect of CRT-D or CRT-P vs. medical therapy on all-cause
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Baseline clinical characteristics of patients
with ischaemic aetiology of cardiomyopathy who
received cardiac resynchronization therapy with
implantable cardioverter defibrillator and cardiac
resynchronization therapy with pacemaker
Clinical parameters
in ischaemic patients
CRT-D
patients
(n= 220)
CRT-P
patients
(n= 235)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age at enrolment (years) 65.8± 9.9 69.7± 8.4*
Female 23 (11) 52 (22)*
Secondary prevention 124 (56) 29(12)*
QRS (ms) 159.3± 26.6 167.7± 30.3*
Diabetes mellitus 85 (39) 96 (41)
Hypertension 156 (71) 178 (76)
Prior MI 178 (81) 159 (68)*
Prior PCI 123 (56) 131 (56)
Prior CABG 86 (39) 65 (28)*
Paroxysmal atrial fibrillation 37 (17) 30 (13)
Permanent atrial fibrillation 49 (22) 75 (32)*
Creatinine (μmol/L) 118.3± 39.0 121.4± 46.6
Urea (mM/L) 10.2± 5.3 10.5± 4.9
Medications
Beta-blockers 197 (90) 207 (88)
ACE inhibitor/ARB 191 (86) 204 (87)
Diuretics 172 (78) 193 (82)
Aldosterone antagonist 133 (60) 126 (54)
Amiodarone 96 (44) 43 (18)*
Echocardiography
LVEF, % 28.5± 6.7 29.3± 7.6
LVEDD, mm 64.9± 9.5 63.0± 9.3*
LVESD, mm 54.1± 9.8 52.4±10.1
Values are given as a percentage of patients or mean± SD.
CABG, coronary artery bypass graft; CRT-D, cardiac resynchronization therapy
with implantable cardioverter defibrillator; CRT-P, cardiac resynchronization
therapy with pacemaker; LVEDV, left ventricular end-diastolic volume; LVESV, left
ventricular end-systolic volume; MI, myocardial infarction.
*P< 0.05 for comparison between CRT-P and CRT-D patients.
mortality in patients with advanced heart failure (NYHA functional
class III or IV symptoms).3 The COMPANION trial investigated
CRT-D implantation vs. optimal medical therapy and CRT-P implan-
tation vs. optimal medical therapy; however, the trial was neither
designed, nor powered to compare the effect of CRT-D vs. CRT-P
implantation on all-cause mortality, and therefore does not provide
conclusive data for the clinician.4
The Cardiac Resynchronization Heart Failure (CARE-HF) trial
compared CRT-P implantation with standard medical therapy and
showed a significant mortality reduction in advanced heart failure
patients with an implanted CRT-P. Furthermore, in the extended
follow-up of patients enrolled in CARE-HF, the authors demon-
strated that patients implanted with a CRT-P alone derived a sig-
nificant reduction in the risk for SCD.16 Several other studies have
shown that CRT alone reduces the risk of ventricular tachyarrhyth-
mias and SCD due to LV reverse remodelling17 and as a result
of the beneficial effects of CRT on the neurohormonal system.18
This brings into question whether improvements in cardiac func-
tion and in the neurohormonal status resulting from CRT-P alone ..
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Table 4 Baseline clinical characteristics of patients
with non-ischaemic aetiology of cardiomyopathy who
received cardiac resynchronization therapy with
implantable cardioverter defibrillator and cardiac
resynchronization therapy with pacemaker
Clinical parameters
in non-ischaemic
patients
CRT-D
patients
(n= 209)
CRT-P
patients
(n= 458)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age at enrolment (years) 61.9± 11.6 64.6± 11.1*
Female 164 (78) 316 (69)*
Secondary prevention 118 (56) 6 (1)*
QRS (ms) 156.9± 27.6 164.2± 26.2*
Diabetes mellitus 49 (23) 145 (32)*
Hypertension 121 (58) 249 (55)
Paroxysmal atrial fibrillation 32 (15) 64 (14)
Permanent atrial fibrillation 47 (23) 117 (26)*
Creatinine (μmol/L) 109.1± 48.5 114.1± 57.4
Urea (mM/L) 9.3± 4.9 10.1± 7.2
Medications
Beta-blockers 179 (86) 375 (82)
ACE inhibitor/ARB 176 (84) 379 (83)
Diuretics 156 (75) 329 (72)
Aldosterone antagonist 126 (60) 242 (53)
Amiodarone 84 (40) 96 (21)*
Echocardiography
LVEF, % 26.4± 5.8 27.5± 7.0
LVEDD, mm 66.3± 10.3 65.0±10.1
LVESD, mm 56.0± 10.3 54.5±10.7
Values are given as a percentage of patients or mean± SD.
CABG, coronary artery bypass graft; CRT-D, cardiac resynchronization therapy
with implantable cardioverter defibrillator; CRT-P, cardiac resynchronization
therapy with pacemaker; LVEDV, left ventricular end-diastolic volume; LVESV, left
ventricular end-systolic volume; MI, myocardial infarction.
*P< 0.05 for comparison between CRT-P and CRT-D patients.
can sufficiently lower the risk of ventricular tachyarrhythmias such
that the incremental benefit from CRT with defibrillator therapy
would be of limited value.
This may be the reason why several meta-analyses comparing the
efficacy of CRT-D over CRT-P in patients with a primary indication
for CRT have failed to show an incremental benefit of adding defib-
rillation therapy to CRT.5–7 The risk of ventricular arrhythmias and
SCD may be sufficiently reduced with CRT-P alone. Furthermore,
CRT-D devices have a significantly higher cost and their widespread
use remains limited especially in emerging countries that have fixed
budgets for healthcare and where healthcare utilization is based on
cost–benefit analysis.8 In addition, the complex design of defibril-
lator leads presents additional challenges including a higher risk of
lead failure in the CRT-D systems.8
Despite these great concerns, there is currently no consensus on
in which patients CRT-P alone could be considered. The physician
needs to estimate costs, benefit, and risks based on the individual
patients. Clinicians in many countries face challenges in reimburse-
ment of CRT devices, and expected future healthcare reforms will
lead to additional scrutiny of expensive medical device therapies.9
Until clinical guidelines or consensus statements become available,
© 2014 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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our results may help clinicians identify patients in whom CRT-P
alone may be sufficiently effective in reducing adverse outcomes.
Our results are novel and provocative, suggesting that CRT-D
does not have an incremental benefit over CRT-P in the reduc-
tion of all-cause mortality in non-ischaemic patients. Only patients
with ischaemic aetiology of cardiomyopathy showed a significant
reduction in mortality with an implanted CRT-D as compared
with a CRT-P. The reason for this finding may be that patients
with non-ischaemic cardiomyopathy are known to be at a lower
risk for ventricular tachyarrhythmias particularly in the setting
of CRT-induced reverse remodelling.19 We found a significantly
higher risk of all-cause mortality in patients with ischaemic car-
diomyopathy compared with non-ischaemic cardiomyopathy, and
this difference in the mortality risk may be due to the higher risk
of life-threatening ventricular arrhythmias and SCD in ischaemic
patients. This might also explain the incremental benefit of CRT-D
over CRT-P in ischaemic cardiomyopathy patients. CRT-D is pro-
viding incremental benefit by reducing the risk of SCD and all-cause
mortality in patients with ischaemic cardiomyopathy.
The European CRT survey evaluated baseline clinical
characteristics20 and outcome21 of 2438 CRT patients with
or without an ICD from 13 European countries between Novem-
ber 2008 and June 2009. Similarly to our study, they found that
patients implanted with a CRT-D were younger, they were more
often male, and they more often had ischaemic aetiology of car-
diomyopathy and less often AF. However, the total cohort, as well
as patients implanted with a CRT-D, in the European CRT survey
was much older than the patients in our study (CRT-D patients
68 years vs. 64 years), and the proportion of ischaemic aetiology
of cardiomyopathy was higher (55 % vs. 51% in our study).20 The
outcome data from the European CRT survey suggested that
all CRT-D patients had better survival compared with CRT-P
patients during short-term, 1-year (9–15 months) follow-up.21
Differences in the clinical characteristics such as a higher per-
centage of ischaemic patients and an older age in the European
CRT registry may explain the different findings compared with our
study. However, this needs further evaluation because currently
older patients are more likely to be implanted with a CRT-P device.
Another important observation of our registry data is that there
was a similar improvement in LV function in patients implanted
with a CRT-D vs. a CRT-P. This further underlines that since the
improvement in cardiac function is the same in CRT-D and CRT-P,
therefore the all-cause mortality in ischaemic and non-ischaemic
patients may be equally related to heart failure-related death, but
there is a difference in SCD-related death.
In our study, patients with non-ischaemic cardiomyopathy had
greater improvement in LVEF than those with ischaemic cardiomy-
opathy. This phenomenon is well known and might be explained
by the larger amount of scar tissue and lower contractile reserve
in ischaemic patients that is not reversible by CRT.19 Previous
studies have also shown that LVEF is related to outcome22,23 and
to ventricular arrhythmias.23 Along this line, we speculate that
CRT-D may provide an incremental mortality benefit over CRT-P
in those who are at a higher risk for SCD at implantation (e.g.
ischaemic aetiology), or in those who have less pronounced LV
reverse remodelling from CRT. ..
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.. It is important to note that patients implanted with a CRT-P
alone did not have an increased risk of mortality compared with
those with a CRT-D as shown in this analysis. The mortality risk
was equal to that of those with an implanted CRT-D, with HRs and
P-value close to 1, indicating a neutral effect.
Our study has several limitations. First, this is a retrospective
analysis of a single-centre registry. However, we enrolled every
patient implanted at our centre with a CRT device over a decade.
Data collection was prospectively performed. Secondly, implan-
tation of a CRT-D or a CRT-P device was left to the physician’s
discretion; it was not a randomized treatment and this may present
selection bias. However, our data show ‘real-world’ clinical prac-
tice in Eastern Europe and we did not observe an increased risk
in all-cause mortality in patients implanted with a CRT-P alone.
Thirdly, we may be underpowered in this analysis because the
interaction P-values were borderline significant; however, in the
non-ischaemic group the effect was close to neutral with HRs
close to 1, and the P-value was also close to 1. Previous studies
suggested that an extremely large trial would be needed to have
sufficient power to detect any significant differences in outcomes
between CRT-D and CRT-P. However, it is unlikely that such a
trial will ever be conducted, hence the importance of our study in
aiding clinicians’ decision-making with respect to patients in whom
CRT-P alone would be sufficient. Therefore, large registry data like
ours are essential to broaden clinical knowledge in this field. Fur-
ther observational studies, single- and multicentre registry data,
meta-analyses, and a randomized trial may be needed to confirm
these findings. Fourthly, in our study, the endpoint was all-cause
mortality and data on cardiac or non-cardiac mortality were not
available. However, classification of cardiac and non-cardiac cause
of death is often difficult and unreliable even in randomized clinical
trials.
Conclusion
We demonstrated that in patients with ischaemic cardiomyopathy,
there is an incremental mortality benefit from the implantation
of a CRT-D device over a CRT-P device. However, in patients
with non-ischaemic cardiomyopathy, there was no additional ben-
efit in reduction of all-cause mortality in patients implanted with
CRT-D as compared with CRT-P alone. Furthermore, patients with
ischaemic and non-ischaemic cardiomyopathy with CRT-D or a
CRT-P derived similar echocardiographic improvement. Our find-
ings suggest that implantation of a CRT-P device might be consid-
ered in patients with non-ischaemic aetiology of cardiomyopathy
who are at a low risk of SCD.
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